The global neuromodulation market size accounted for USD 8.09 billion in 2024, grew to USD 9.07 billion in 2025 and is expected to be worth around USD 25.51 billion by 2034, registering a CAGR of 12.17% between 2024 and 2034. The North America neuromodulation market size is calculated at USD 3.72 billion in 2024 and is estimated to grow at a CAGR of 12.29% during the forecast period.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Neuromodulation Market
5.1. COVID-19 Landscape: Neuromodulation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Neuromodulation Market, By Technology
8.1. Neuromodulation Market, by Technology, 2024-2034
8.1.1 Internal Neuromodulation
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. External Neuromodulation
8.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Neuromodulation Market, By Application
9.1. Neuromodulation Market, by Application, 2024-2034
9.1.1. Chronic Pain
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Urinary And Fecal Incontinence
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Migraine
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Failed Back Syndrome
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Parkinson Disease
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Epilepsy
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Tremor
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Depression
9.1.8.1. Market Revenue and Forecast (2021-2034)
9.1.9. Other Applications
9.1.9.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Neuromodulation Market, By Biomaterials
10.1. Neuromodulation Market, by March, 2024-2034
10.1.1. Metallic Biomaterials
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Polymeric Biomaterials
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Ceramic Biomaterials
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Neuromodulation Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Biomaterials(2021-2034)
Chapter 12. Company Profiles
12.1. LivaNova PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Nevro Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Medtronic
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. NeuroSigma
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Neuronetics
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bioventus Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. NeuroPace Inc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. MicroTransponder
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Boston Scientific Corporation
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Abbott
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample